3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
30
Neoplasm Metastasis
10
Carcinoma, Non-Small-Cell Lung
8
Stomach Neoplasms
7
Neoplasms
6
Colorectal Neoplasms
6
Adenocarcinoma
6
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Endometrial Neoplasms
3
Advanced Solid Tumor
3
Triple Negative Breast Neoplasms
2
Sarcoma
2
Prostatic Neoplasms
2
Melanoma
2
HER2-positive Gastric Cancer
2
Gastrointestinal Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Renal Cell
2
Brain Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Solid Cancer
1
Interventions
pembrolizumab
44
Carboplatin
28
Cisplatin
26
Paclitaxel
24
Bevacizumab
21
human papillomavirus vaccine, L1 type 16, 18
16
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
14
atezolizumab
11
Papillomavirus Vaccines
11
Nivolumab
10
tisotumab vedotin
8
Vaccines, Synthetic
8
Gemcitabine
8
Colposcopy
8
Topotecan
7
fludarabine
6
Vaccines
6
Injections
6
Cyclophosphamide
6
spartalizumab
5
balstilimab
5
Pemetrexed
5
Irinotecan
5
Fulvestrant
5
Docetaxel
5
zimberelimab
4
durvalumab
4
Vinorelbine
4
Ipilimumab
4
Interleukin-2
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Uterine Cervical Neoplasms
×
trastuzumab deruxtecan
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled